dapagliflozin
astrazeneca
[]
in pts w/t2d from 4 timi clinical trials, et al developed and validated the timi risk score for kidney disease progression in type 2 diabetes, which helped identify pts at higher risk and who derive greater benefit from sglt2 inhibition. #acc23 
Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.